2025 Year of the Patient
At Digestive Cancers Europe (DiCE), we have always placed patients at the heart of our mission—amplifying their voices, advocating for their nee...
Can a Targeted Cancer Drug Help Prevent Recurrence in Gastro-Oesophageal Cancer?
DECIPHER Trial for patients with gastro-oesophageal adenocarcinoma, tests whether a targeted cancer drug can help patients with a hard-to-treat can...
Reflecting on ENTERO 2024 – A Milestone for Early-Age Onset Digestive Cancers
On November 14 and 15, Digestive Cancers Europe (DiCE) and EuropaColon Portugal proudly hosted ENTERO 2024 in the scenic city of Porto, Portugal.Read
Tevimbra (tislelizumab) Receives New European Recommendations for Oesophageal and Gastric Cancer
Tevimbra (tislelizumab) receives CHMP recommendations for treating PD-L1-positive oesophageal squamous cell carcinoma and gastric/gastroesophageal ...
New Era in Gastric Cancer Treatment: Zolbetuximab Gains EU Approval
On September 20th, 2024, the European Commission approved zolbetuximab with chemotherapy for advanced Gastric and GastroEsophageal Junction cancers...
Positive Response to New Neoadjuvant Treatment Combination for Gastric and Gastroesophageal Cancer
In a recently published study conducted by the Netherlands Cancer Institute, patients with gastric (stomach) cancer or gastroesophageal junction (G...
Celebrating a Lifetime of Achievement: Dr Eric Van Cutsem Honoured as Professor Emeritus
Dr Eric Van Cutsem, world-renowned Professor of Clinical Digestive Oncology and co-founder of Digestive Cancers Europe, was lauded as Professor Eme...
Economist Impact: World Cancer Series Europe
On 20 September, the Belgian delegation of the DiCE Team attended the Economist Impact’s World Cancer Series: Europe in Brussels, proudly sup...
Do You Dare to Think Differently about Cancer?
The Cancer Grand Challenges mission is “Uniting the World’s brightest minds against cancer’s toughest challenges”. Founded by CRUK (Cancer ...
ESMO Study Confirms Precision Oncology Remains Largely Inaccessible to European Cancer Patients
As a European umbrella organisation, DiCE is vocal in addressing the disparities associated with cancer patients’ access to precision medicin...
